Regulatory Focus March 24, 2023
By Ferdous Al-Faruque

The US Food and Drug Administration (FDA) plans to hold at least one public meeting and release several guidances on digital health technologies (DHT) to be used in drug clinical trials by the end of the year. While it has issued guidances on digital health products generally, there is still concern about whether such products are accurate and reliable enough to gather data for the drug development process.

As part of FDA’s commitment under the Prescription Drug User Fee Act (PDUFA VII), the agency published a framework on 23 March on how it plans to address long-standing questions on the use of DHTs in drug clinical trials.

The agency has established a steering committee with staff from its drug, device,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Clinical Trials, Digital Health, FDA, Govt Agencies, Technology, Trends
Related Articles:
To Give Rare Disease Patients Hope, the FDA Must Re-Focus its Efforts
Opinion: Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it
FDA clears heart rhythm AI that turns smartphones into medical devices
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Accelerated Approval Pathway for Cancer Drugs: Does It Work?

Share This Article